Effects of proton pump inhibitor FR167356 on osseointegration of dental implant in osteoporosis rabbits

doi:10.3969/j.issn.2095-4344.2014.33.015

Abstract

Abstract:

BACKGROUND: Vacuolar proton pump on the cytoplasmic membrane of osteoclasts is an essential enzyme for bone histolysis. Vacuolar proton pump inhibitor can significantly inhibit the in vitro cultured osteoclasts.
OBJECTIVE: To observe the effect of proton pump inhibitor FR167356 on the osseointegration of dental implant of osteoporosis rabbits.
METHODS: A total of 24 female Japanese white rabbits aged 5 months were randomly divided into three groups: ovariectomy (OVX) group, FR167356 group and shamed operation group. Each group contained eight rabbits. Rabbits of OVX group and FR167356 group received a surgical removal of bilateral ovaries, while rabbits of sham operation group had a surgical removal of equivalent adipose tissue beside the ovaries. Two titatium implants (8 mm long, 3.3 mm diameter) were installed into bilateral proximal tibias respectively 12 weeks after OVX operation. FR167356 was administrated by muscle injection in FR167356 group; meanwhile equivalent normal saline was administrated in the OVX group and sham operation group. At 4 and 8 weeks after implantation, animals in each group were sacrificed respectively for X-ray imaging, histomorphology, and mechanical test.
RESULTS AND CONCLUSION: X-ray examination showed that at 4 weeks, the implants in the OVX group exhibited a high resistance projective image, low density image of clearance screw thread, and clear boundaries between bone tissue than the other two group. At 12 weeks, the density of the clearance screw thread in sham operation group and FR167356 group was more closer to the surrounding bone tissue when compared with the OVX group, the boundaries between the implant and the surrounding bone tissue disappeared more apparently, and no significant differences were found between the two groups. Histomorphology observation revealed that, at 4 weeks after implantation, new bone with porous and trabecular extended along the implant surface to the root direction in FR167356 and sham operation groups. There were no significant differences in the two groups. At 12 weeks after implantation, the bone mass around implant was increased greatly and the trabecular grew thicker. This phenomenon was not observed in the OVX group. Mechanic test showed that at 4 and 12 weeks after implantation, the maximum pullout force in the OVX group was significantly lower than that in the other two groups. Local application of FR167356 can significantly improve the osseointegration of the implant in osteoporosis rabbits.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: dental implants, osseointegration, osteoporosis, proton pump inhibitor

CLC Number:

R318

Zhang Peng, Shi Wen-yi, Guo Da-wei, Yu Jiang-bo, Song Ling, Zhang Chun-yan, Cao Yang. Effects of proton pump inhibitor FR167356 on osseointegration of dental implant in osteoporosis rabbits[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(33): 5334-5340.

Figures/Tables 5

References

[1]Hwang D, Wang HL. Medical contraindications to implant therapy: part II: relative contraindications. Implant Denti. 2007;16(1):13-23.
[2]Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants. 2009;24 Suppl:12-27.
[3]席光伟,王学玲,宫琳,等.辛伐他汀涂层内固定对大鼠骨质疏松骨折愈合晚期的影响[J].中国组织工程研究, 2013,17(51): 8827-8833.
[4]Jiang GZ, Matsumoto H, Hori M, et al. Correlation among geometric, densitometric, and mechanical properties in mandible and femur of osteoporotic rats. J Bone Miner Metab. 2008;26(2):130-137.
[5]Brennan-Calanan RM, Genco RJ, Wilding GE, et al. Osteoporosis and oral infection: independent risk factors for oral bone loss. J Dent Res. 2008;87(4):323-327.
[6]Chang PC, Lang NP, Giannobile WV. Evaluation of functional dynamics during osseointegration and regeneration associated with oral implants. Clin Oral Implants Res. 2010; 21(1):1-12.
[7]马俊岭,郭海英,阳晓东.骨质疏松症的流行病学概况[J].中国全科医学,2009,12(9):1744-1746.
[8]Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants. 2003;18(2):218-223.
[9]Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285(33): 25103-25108.
[10]Al-Bataineh MM, Gong F, Marciszyn A, et al. Regulation of the Proximal Tubule Vacuolar H+-ATPase by PKA and AMP-Activated Protein Kinase. Am J Physiol Renal Physiol. 2014;306(9):F981-995.
[11]Laitala T, Väänänen HK. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H (+)- ATPase. J Clin Invest. 1994;93(6):2311.
[12]Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nature Genet. 2000;25(3):343-346.
[13]Kartner N, Manolson MF. Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H+-ATPase as an emerging target. Expert Opin Drug Discov. 2014;9(5):505-522.
[14]Niikura K, Takano M, Sawada M. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol. 2004;142(3):558-566.
[15]方忠,杨琴,李锋,等.去势法兔骨质疏松模型建立的探讨[J].中国骨质疏松杂志,2005,11(2):202-205.
[16]吴松涛,孟维艳,蔡青,等.PTH (1-34)对兔骨质疏松种植体骨结合影响的研究[J].实用口腔医学杂志, 2011,27(2):181-184.
[17]Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol. 2009;212(3):341-346.
[18]Price PA, June HH, Buckley JR, et al. SB 242784, a selective inhibitor of the osteoclastic V-H+-ATPase, inhibits arterial calcification in the rat. Circ Res. 2002;91(6):547-552.
[19]Nyman JKE, Väänänen HK. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform. Calcif Tissue Int. 2010;87(3):273-283.
[20]Tarakida A, Higuchi T, Mizunuma H. [Evidence of hormone replacement therapy for osteoporosis]. Clin Calcium. 2008; 18(10):1434-1441.
[21]Palacios S. Advances in hormone replacement therapy: making the menopause manageable. BMC Women's Health. 2008;8(1):22.
[22]侯玉东,余萍萍,韩晓鹏,等.雌激素干预吸烟骨质疏松大鼠种植体周围的骨沉积[J].中国组织工程研究,2012,16(46):8556-8560.
[23]Minsk L, Polson AM. Dental implant outcomes in postmenopausal women undergoing hormone replacement. Compend Contin Educ Dent. 1998;19(9):859-862.
[24]Wang Y, Yang X, Li X, et al. Knowledge and personal use of menopausal hormone therapy among Chinese obstetrician- gynecologists: results of a survey. Menopause. 2014. [Epub ahead of print].
[25]Dikicier E, Karaçayl? Ü, Dikicier S, et al. Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats. J Craniomaxillofac Surg. 2014. pii: S1010-5182(14)00041-9.
[26]张玉芹,邓久鹏,戚孟春,等.局部应用唑来膦酸对骨质疏松大鼠种植体骨结合的影响[J].中国老年学杂志, 2012,32(15):3227- 3229.
[27]李春艳,周延民,王林,等.阿仑膦酸钠对骨质疏松种植体骨结合影响的力学研究[J].华西口腔医学杂志,2011,29(3):328-329.
[28]Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis Expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324-333.
[29]李国宾,贾素侠,陈旻生,等.辛伐他汀对骨质疏松患者种植体周围骨的影响[J].中国实用医药,2012,7(18):49-50.
[30]Ahn SJ, Leesungbok R, Lee SW, et al. Differences in implant stability associated with various methods of preparation of the implant bed: An in vitro study. J Prosthet Dent. 2012;107(6): 366-372.
[31]蒋柳宏,景向东,闫春歌,等.仙灵骨葆对骨质疏松状态下纯钛种植体骨结合的影响[J].新中医,2008,40(4):100-101.
[32]Ustun Y, Erdogan O, Kurkcu M, et al. Effects of low-intensity pulsed ultrasound on dental implant osseointegration: a preliminary report. Eur J Dent. 2008;2:254.
[33]Danoux CB, Barbieri D, Yuan H, et al. In vitro and in vivo bioactivity assessment of a polylactic acid/hydroxyapatite composite for bone regeneration. Biomatter. 2014;4(1): e27664.
[34]张帆,陈晖,程志鹏.加速口腔种植体愈合的相关性研究现状[J]. 全科医学临床与教育,2009,7(5):503-305.
[35]Sørensen MG, Henriksen K, Neutzsky‐Wulff AV, et al. Diphyllin, a Novel and Naturally Potent V‐ATPase Inhibitor, Abrogates Acidification of the Osteoclastic Resorption Lacunae and Bone Resorption. J Bone Mineral Res. 2007; 22(10):1640-1648.
[36]Niikura K. Comparative analysis of the effects of a novel vacuolar adenosine 5'-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats. J Periodontol. 2006;77(7):1211-1216.
[37]Kempen DHR, Lu L, Heijink A, et al. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials. 2009;30(14):2816-2825.
[38]Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005;20(9):1579-1588.
[39]Nishisho T, Hata K, Nakanishi M, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011;9(7): 845-855.
[40]Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, et al. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev. 2009;35(8):707-713.